CClinicalTrials.gg
Not yet recruitingNCT06962553Updated May 8, 2025

Nurses' Competence and Role in Survival Prediction and Prognostic Communication

An observational study in Advanced Cancer, Terminal Malignant Tumors and Hospices, sponsored by National Taiwan University Hospital. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by National Taiwan University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
152
Sex
All
01

Study summary

[Background] Nurses' roles in survival prediction and prognostic communication have historically been limited due to role delineation, lack of formal training, and cultural norms. In Taiwan and other cultural contexts, prognostic discussions have traditionally been the purview of physicians. However, evolving paradigms in health communication, practical realities in nursing practice, and the expanded responsibilities of advanced practice nurses have highlighted the importance of nurses in this domain. Nurses frequently engage in "foreseeing" prognostic indicators through daily patient care, and emerging evidence suggests their prognostic accuracy is often comparable to or exceeds that of physicians. Despite this, the exact scope of nurses' roles in prognostication remains unclear, creating gaps in understanding the contributions, benefits, and associating factors of nurses' involvement of prognostication process.

[Aim] This mixed-methods study aims to examine hospice nurses' competencies and roles in prognostication, with a focus on their survival prediction accuracy, confidence, influencing factors, and self-perceived responsibilities.

[Method] This three-year, cross-national study adopts an explanatory sequential mixed-methods design. First, the quantitative phase utilizes a prospective cohort design, recruiting palliative nurses and physicians from ten palliative care sites across three countries. Eligible clinicians include nurses and physicians who provide care for patients with advanced cancer in palliative care settings or oncologic wards. Participating clinicians will provide weekly prognostic predictions for targeted patients and rate their confidence levels. Patients' demographic and disease-related information will also be collected to estimate survival using prediction tools. Data collection will conclude upon the patient's death or discharge. Based on the results of the quantitative phase, a descriptive qualitative study will be conducted to purposefully recruit nurses with varying levels of prediction accuracy and confidence from the quantitative phase. Semi-structured interviews will be carried out to gather qualitative data on their perspectives regarding prognostication, with a particular focus on their roles. The estimated sample size for quantitative phase is 152 nurse-physician dyads (based on 152 patients), while 20-30 nurses are expected to participate in the qualitative phase.

[Data Analysis] Descriptive statistics, area under the receiver operating characteristic (ROC) curve (AUC), Cohen's kappa, weighted kappa, McNemar's test, and ordinal logistic regression will be used to analyze quantitative data. Qualitative data will be analyzed using conventional content analysis. Nurses' Competence and Role in Survival Prediction and Prognostic Communication.

[Expecting Outcomes and Conclusion] This project uniquely highlights nurses' contributions to prognostication, aiming to generate evidence that informs future research, clinical practice, and policy development. The findings will shed light on nurses' roles, functions, potential benefits, and the barriers the face in prognostication.

02

Conditions studied

  • Advanced Cancer
  • Terminal Malignant Tumors
  • Hospices

Browse trials for

Keywords

  • survival analysis
  • projections and predictions
  • palliative care
  • hospice and palliative care nursing
  • nurses's role
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 152 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The research team at each site will identify eligible patients in the palliative and hospice unit and invite their physicians and nurses to participate the study.

Inclusion criteria

[Inclusion criteria for patients]

  • 18 years old or older
  • Diagnosed with advanced solid cancer, including locally extensive or metastasis cancer
  • Patients admitted to palliative care units or oncology units in the participating institutions.

[Inclusion criteria for clinicians]

  • Nurses who are the primary care nurse of the included patients
  • Nurses who care for the included patients for at least one shift
  • Nurses who work in palliative and hospice units or team, or oncology units for over 6 months.
  • Physicians who are palliative care specialists and/or physicians with palliative care trainings
  • Physicians who are the primary care physician of the included patient.

Exclusion criteria

Exclusion Criteria:

  • Patients with hematological malignancies are excluded.
  • A participated clinicians can only participate in the study up to three times, clinicians who participate in the study for more than three times are excluded.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
152 participants (estimated)
Patient registry
No

Groups and cohorts

  • Nurses
  • Doctors
06

What researchers measure

Primary outcomes

  1. Palliative nurses' accuracy in making survival prediction

    The results of predicted survival time estimated by participants should be specified within a range of days to weeks. The accuracy will be measured by comparing their results of prediction to: (1) the patients actual survival, (2) those of physicians, and (3) survival prediction derived from prognostic tools.

    Time frame: From enrollment to the end of treatment at 2.5 years

  2. Palliative nurses' levels of confidence in making prognostic predictions

    The level of confidence will be measured on the scale of 0 to 10.

    Time frame: From enrollment to the end of treatment at 2.5 years

Secondary outcomes

  1. Relationship between palliative nurses' demographic variables, prognostic confidence, and survival prediction accuracy

    Analysis of the association between nurses' demographic factors (e.g., age, years of experience, ward type) and their level of prognostic confidence and accuracy in predicting survival time for terminal cancer patients. Measured using structured questionnaires and comparison with actual survival outcomes.

    Time frame: From enrollment to the end of treatment at 2.5 years

  2. Palliative nurses' perceptions of their roles in prognostic prediction

    Thematic analysis of interview transcripts to explore how nurses describe their roles in prognostic prediction

    Time frame: From enrollment to the end of treatment at 2.5 years

  3. Themes which affect palliative nurses' prognostic prediction and level of confidence

    Identification and thematic analysis of key factors influencing palliative care nurses' prognostic predictions and their level of confidence. Themes will be derived from qualitative data collected through semi-structured and analyzed using content or thematic analysis.

    Time frame: From enrollment to the end of treatment at 2.5 years

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06962553
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
May 8, 2025
Start date
May 8, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 8, 2025

Study contacts

Chia Chung Tang, PhD
Contact
chiatang@ntu.edu.tw
+88623123456 ext. 288436
Tzu Yuan Yeh, BS
Contact
R10426035@ntu.edu.tw
+886912520079

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion